{"id":37488,"date":"2020-11-10T11:42:53","date_gmt":"2020-11-10T16:42:53","guid":{"rendered":"https:\/\/reviewofmm.com\/?p=37488"},"modified":"2024-02-02T10:55:12","modified_gmt":"2024-02-02T15:55:12","slug":"coopervisions-brilliant-futures-myopia-management-program-expands-globally","status":"publish","type":"post","link":"https:\/\/reviewofmm.com\/coopervisions-brilliant-futures-myopia-management-program-expands-globally\/","title":{"rendered":"CooperVision\u2019s Brilliant Futures Myopia Management Program Expands Globally"},"content":{"rendered":"
November 10, 2020<\/strong><\/p>\n Less than a year after debuting its\u00a0Brilliant Futures\u00a0 – Myopia Management Program<\/a>\u00a0featuring the\u00a0MiSight 1 day contact lens<\/a>\u00a0in the United States, CooperVision is now expanding the comprehensive approach to multiple countries, including the United Kingdom, Russia, Spain, Portugal, Canada, South Korea, and Taiwan.\u00a0This\u00a0seeks to create a new standard of care by creating the optimal environment for compliance, satisfaction, clinical outcomes and long-term loyalty.<\/p>\n \u201cSeveral years from now, I believe we will look back at late 2020 as an inflection point in the global myopia management movement,\u201d said\u00a0Daniel McBride, president of CooperVision. \u201cNever before has there been this degree of momentum, driven in large part by substantial investments CooperVision is making in evidence-based science, innovative products, and comprehensive clinical and practice management education in the form of Brilliant Futures. Partnering with the optometry, ophthalmology and pediatric health communities, we have a real opportunity to change the lives of countless children in the decades ahead.\u201d<\/p>\n Brilliant Futures has attracted robust participation during its selective U.S. rollout, with more than 1,500 eye care professionals now certified to fit MiSight 1 day. The innovative lens is the first and only soft contact lens the U.S. Food and Drug Administration has approved* for slowing the progression of myopia in children, who at initiation of treatment are 8-12 years of age.1<\/sup><\/span>\u00a0During the past several weeks, a\u00a0nationwide parent-focused advertising campaign<\/a>\u00a0featuring entrepreneur and actress Sarah Michelle Gellar\u2014believed to be possibly the world\u2019s largest-ever consumer myopia management awareness initiative\u2014further accelerated adoption.<\/p>\n Complementing that success, Brilliant Futures is now coming to countries where MiSight 1 day has been previously available, such as the\u00a0United Kingdom<\/a>\u00a0in October.\u00a0Indie Grewal<\/a>, Optometrist and President of the British Contact Lens Association (BCLA), says myopia management \u201chas the potential to revolutionize\u00a0clinical outcomes\u00a0and can allow us to\u00a0change the trajectory of childhood myopia\u00a0in practice.\u201d \u00a0The program will also be introduced this month in\u00a0Spain<\/a>\u00a0and\u00a0Portugal<\/a>, which are current MiSight 1 day markets.<\/p>\n In\u00a0Canada<\/a>, where MiSight 1 day prescribing has steadily grown in recent years, the Brilliant Futures program became available last week. A pilot study conducted by the Centre for Ocular Research & Education (CORE), the University of Waterloo\u2019s School of Optometry & Vision Science and the Canadian National Institute for the Blind determined that almost 30 percent of Canadian children aged 11-13 are myopic<\/a>.2<\/sup><\/span><\/p>\n Likewise, the program is launching in countries concurrent with the first availability of MiSight 1 day. In\u00a0Russia<\/a>, this coincides with MiSight 1 day\u2019s new approval as a therapeutic contact lens and includes ECP-focused digital media and virtual events that began in late October. The lens is newly approved in South Korea for slowing myopia progression, with the program launch commencing this November.<\/p>\n Brilliant Futures was unveiled in Taiwan<\/a>\u00a0in late September, where MiSight 1 day has become the first Taiwan Food and Drug Administration-approved product to control the progression of myopia in children. Myopia is estimated to affect approximately 960,000 Taiwanese elementary and middle school students.3<\/sup><\/span><\/p>\n Advancing Myopia Management in China<\/u><\/p>\n